Page 1 of 44
PMH-C PSI MEDICATIONS AND CAM COURSE EXAM
2026/2027 COMPLETE (100) CURRENT TESTING
QUESTIONS AND CORRECT ANSWERS WITH DETAILED
RATIONALES.
PMH-C
Prepare for the PMH-C PSI Medications and CAM Course Exam with a focused study
resource designed to reinforce key concepts in perinatal psychopharmacology and
complementary and alternative medicine. It supports review of medication
considerations during pregnancy and lactation, antidepressants, anxiolytics, mood
stabilizers, antipsychotics, CAM therapies, and clinical risk-benefit decision-making.
Use the material to strengthen knowledge, improve clinical reasoning, and identify
areas that may require additional review before the examination. This resource is best
suited for PMH-C candidates, perinatal mental health professionals, and healthcare
providers preparing for the PSI Perinatal Mental Health Certification examination.
MULTIPLE CHOICE.
SECTION 1: GENERAL PRINCIPLES OF PERINATAL
PSYCHOPHARMACOLOGY (Questions 1–15)
Question 1:
A pregnant patient with moderate depression asks about medication safety.
Which of the following is the most important principle to communicate?
A) "Medications should be avoided entirely during pregnancy."
B) "Untreated mental illness also poses risks to both mother and baby."
C) "All antidepressants carry the same risk profile."
D) "Medication is never needed if you are receiving psychotherapy."
Answer: B) Untreated mental illness also poses risks to both mother and
baby.
Rationale: A foundational principle of perinatal psychopharmacology is
that "exposure always occurs, be it to treatment or illness". Untreated
maternal depression can be neurotoxic and developmentally damaging.
, Page 2 of 44
There is no single "safest" or "best" medication for use during pregnancy,
postpartum, or lactation—the decision must be individualized.
Question 2:
According to APA and ACOG guidelines for perinatal depression treatment,
which of the following is recommended for mild-to-moderate depression?
A) Immediate medication initiation
B) Psychotherapy as first-line treatment
C) Inpatient psychiatric hospitalization
D) Electroconvulsive therapy (ECT)
Answer: B) Psychotherapy as first-line treatment
Rationale: For mild-to-moderate perinatal depression, psychotherapy is
the first-line treatment. Non-pharmacologic interventions should be
maximized before starting medications. Medications should be continued
if the patient is already stable on them. Severe/recurrent depression
typically warrants medication continuation, and suicidal/psychotic
presentations require immediate referral to hospital or psychiatric care.
Question 3:
What is the prevalence of antidepressant use during pregnancy?
A) Approximately 5% of pregnant women
B) Approximately 13% of pregnant women
C) Approximately 25% of pregnant women
D) Approximately 50% of pregnant women
Answer: B) Approximately 13% of pregnant women
Rationale: Approximately 13% of pregnant women are prescribed
antidepressants. Additionally, approximately 50% of pregnancies are
unplanned, meaning early medication exposure has often already
occurred before the patient knows she is pregnant.
, Page 3 of 44
Question 4:
Why is there so much conflicting data on medication safety in perinatal
populations?
A) There are many randomized, double-blind, placebo-controlled trials
B) Most studies are retrospective database and case-control studies
C) All studies are conducted on pregnant women
D) There is no research on this topic
Answer: B) Most studies are retrospective database and case-control
studies
Rationale: There are no randomized, double-blind, placebo-controlled
trials in this population for ethical reasons. Most studies are retrospective
database and case-control studies, which may involve voluntary reporting
and are confounded by illness exposure. Confounding variables include
other prescription/non-prescription medications, nutrition,
alcohol/cigarettes, genetics, obesity, method of delivery, environmental
toxins, and maternal/paternal age.
Question 5:
Which of the following is NOT a confounding variable when assessing risk of
medication exposure in pregnancy?
A) Maternal/paternal age
B) Obesity
C) Method of delivery
D) The medication itself
Answer: D) The medication itself
Rationale: The medication itself is the exposure being studied, not a
confounding variable. Confounding variables include other
prescription/non-prescription medications, nutrition, alcohol/cigarettes,
genetics, obesity, method of delivery, environmental toxins, and
maternal/paternal age. These factors can make it difficult to isolate the
effects of the medication from other influences.
, Page 4 of 44
Question 6:
A patient who is stable on an antidepressant and becomes pregnant should:
A) Discontinue the medication immediately
B) Continue the medication after discussing risks and benefits
C) Switch to a different medication regardless of efficacy
D) Only take the medication in the third trimester
Answer: B) Continue the medication after discussing risks and benefits
Rationale: For patients with severe or recurrent depression who are
already on medication, APA and ACOG guidelines recommend continuing
the medication. The risk of relapse with discontinuation often outweighs
the risks of medication exposure. Non-pharmacologic interventions
should be maximized, and the decision should be individualized with
shared decision-making.
Question 7:
Which of the following is true regarding neonatal adaptation syndrome (NAS)
related to SSRI exposure?
A) It occurs in 80-90% of exposed infants
B) Symptoms are dose-dependent
C) Symptoms are transient and self-limited, lasting ≤ 2 weeks
D) It is a permanent neurological condition
Answer: C) Symptoms are transient and self-limited, lasting ≤ 2 weeks
Rationale: Neonatal adaptation syndrome (NAS) occurs in 10-30% of SSRI-
exposed infants. Symptoms include jitters, irritability, hypertonia, feeding
difficulties, tremor, GI/sleep disturbance, high-pitched cry, and
tachypnea. Symptoms are transient and self-limited, lasting ≤ 2 weeks.
The syndrome is not dose-dependent, and there is no benefit to changing
dose or discontinuing medications in the third trimester. Breastfeeding
may be protective.
PMH-C PSI MEDICATIONS AND CAM COURSE EXAM
2026/2027 COMPLETE (100) CURRENT TESTING
QUESTIONS AND CORRECT ANSWERS WITH DETAILED
RATIONALES.
PMH-C
Prepare for the PMH-C PSI Medications and CAM Course Exam with a focused study
resource designed to reinforce key concepts in perinatal psychopharmacology and
complementary and alternative medicine. It supports review of medication
considerations during pregnancy and lactation, antidepressants, anxiolytics, mood
stabilizers, antipsychotics, CAM therapies, and clinical risk-benefit decision-making.
Use the material to strengthen knowledge, improve clinical reasoning, and identify
areas that may require additional review before the examination. This resource is best
suited for PMH-C candidates, perinatal mental health professionals, and healthcare
providers preparing for the PSI Perinatal Mental Health Certification examination.
MULTIPLE CHOICE.
SECTION 1: GENERAL PRINCIPLES OF PERINATAL
PSYCHOPHARMACOLOGY (Questions 1–15)
Question 1:
A pregnant patient with moderate depression asks about medication safety.
Which of the following is the most important principle to communicate?
A) "Medications should be avoided entirely during pregnancy."
B) "Untreated mental illness also poses risks to both mother and baby."
C) "All antidepressants carry the same risk profile."
D) "Medication is never needed if you are receiving psychotherapy."
Answer: B) Untreated mental illness also poses risks to both mother and
baby.
Rationale: A foundational principle of perinatal psychopharmacology is
that "exposure always occurs, be it to treatment or illness". Untreated
maternal depression can be neurotoxic and developmentally damaging.
, Page 2 of 44
There is no single "safest" or "best" medication for use during pregnancy,
postpartum, or lactation—the decision must be individualized.
Question 2:
According to APA and ACOG guidelines for perinatal depression treatment,
which of the following is recommended for mild-to-moderate depression?
A) Immediate medication initiation
B) Psychotherapy as first-line treatment
C) Inpatient psychiatric hospitalization
D) Electroconvulsive therapy (ECT)
Answer: B) Psychotherapy as first-line treatment
Rationale: For mild-to-moderate perinatal depression, psychotherapy is
the first-line treatment. Non-pharmacologic interventions should be
maximized before starting medications. Medications should be continued
if the patient is already stable on them. Severe/recurrent depression
typically warrants medication continuation, and suicidal/psychotic
presentations require immediate referral to hospital or psychiatric care.
Question 3:
What is the prevalence of antidepressant use during pregnancy?
A) Approximately 5% of pregnant women
B) Approximately 13% of pregnant women
C) Approximately 25% of pregnant women
D) Approximately 50% of pregnant women
Answer: B) Approximately 13% of pregnant women
Rationale: Approximately 13% of pregnant women are prescribed
antidepressants. Additionally, approximately 50% of pregnancies are
unplanned, meaning early medication exposure has often already
occurred before the patient knows she is pregnant.
, Page 3 of 44
Question 4:
Why is there so much conflicting data on medication safety in perinatal
populations?
A) There are many randomized, double-blind, placebo-controlled trials
B) Most studies are retrospective database and case-control studies
C) All studies are conducted on pregnant women
D) There is no research on this topic
Answer: B) Most studies are retrospective database and case-control
studies
Rationale: There are no randomized, double-blind, placebo-controlled
trials in this population for ethical reasons. Most studies are retrospective
database and case-control studies, which may involve voluntary reporting
and are confounded by illness exposure. Confounding variables include
other prescription/non-prescription medications, nutrition,
alcohol/cigarettes, genetics, obesity, method of delivery, environmental
toxins, and maternal/paternal age.
Question 5:
Which of the following is NOT a confounding variable when assessing risk of
medication exposure in pregnancy?
A) Maternal/paternal age
B) Obesity
C) Method of delivery
D) The medication itself
Answer: D) The medication itself
Rationale: The medication itself is the exposure being studied, not a
confounding variable. Confounding variables include other
prescription/non-prescription medications, nutrition, alcohol/cigarettes,
genetics, obesity, method of delivery, environmental toxins, and
maternal/paternal age. These factors can make it difficult to isolate the
effects of the medication from other influences.
, Page 4 of 44
Question 6:
A patient who is stable on an antidepressant and becomes pregnant should:
A) Discontinue the medication immediately
B) Continue the medication after discussing risks and benefits
C) Switch to a different medication regardless of efficacy
D) Only take the medication in the third trimester
Answer: B) Continue the medication after discussing risks and benefits
Rationale: For patients with severe or recurrent depression who are
already on medication, APA and ACOG guidelines recommend continuing
the medication. The risk of relapse with discontinuation often outweighs
the risks of medication exposure. Non-pharmacologic interventions
should be maximized, and the decision should be individualized with
shared decision-making.
Question 7:
Which of the following is true regarding neonatal adaptation syndrome (NAS)
related to SSRI exposure?
A) It occurs in 80-90% of exposed infants
B) Symptoms are dose-dependent
C) Symptoms are transient and self-limited, lasting ≤ 2 weeks
D) It is a permanent neurological condition
Answer: C) Symptoms are transient and self-limited, lasting ≤ 2 weeks
Rationale: Neonatal adaptation syndrome (NAS) occurs in 10-30% of SSRI-
exposed infants. Symptoms include jitters, irritability, hypertonia, feeding
difficulties, tremor, GI/sleep disturbance, high-pitched cry, and
tachypnea. Symptoms are transient and self-limited, lasting ≤ 2 weeks.
The syndrome is not dose-dependent, and there is no benefit to changing
dose or discontinuing medications in the third trimester. Breastfeeding
may be protective.
